现在位置：百拇书刊 > 国外期刊 > 肿瘤与内分泌 > 2005年.第2期 《肿瘤与内分泌》.2005年.第2期  * Development of strategies for the use of anti-growth factor treatments  * Inhibitors of growth factor signalling  * Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy  * Clinical trials of intracellular signal transductions inhibitors for breast cancer — a strategy to overcome endocrine resistance  * Overview of tyrosine kinase inhibitors in clinical breast cancer  * Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy  * Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience  * Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience  * Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast canc  * Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X  * Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E  * Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation  * Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity  * The NFB pathway and endocrine-resistant breast cancer  * Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor t  * The epidermal growth factor receptor family  * Overview of the impact of conventional systemic therapies on breast cancer  * Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer  * ER is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components  * Malign cystic glucagonoma presented with diabetic ketoacidosis: case report with an update  * Chromosomal instability predicts metastatic disease in patients with insulinomas  * Enhanced protein kinase B/Akt signalling in pituitary tumours  * Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inosi  * The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1  * Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human br  * Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement  * Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl–current associated with neuroendocrine differentiation of pros  * Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in  * BRAF mutation in thyroid cancer  * Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours  * Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical mark  * Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture  * Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and re  * Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis  * Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma  * Tissue inhibitor of metalloproteinases-1 in breast cancer  * Breast-tissue sampling for risk assessment and prevention  * Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis an